Korean MedTech in Brazil: Navigating ANVISA's B-GMP Certification

This episode unpacks the most critical step for Korean medical device companies entering the Brazilian market: ANVISA's Brazilian GMP (B-GMP) certification. We detail the mandatory B-GMP requirements for Class III and IV devices and compare the two main compliance pathways. Discover the significant time and cost advantages of leveraging MDSAP certification, which can extend certificate validity to four years and potentially waive on-site inspections, versus the timeline and costs associated with a direct ANVISA audit at your Korean facility. We also explain how to use your existing K-GMP certification as a strong foundation for B-GMP readiness. - What is B-GMP and why is it essential for selling high-risk medical devices in Brazil? - How can MDSAP certification streamline the ANVISA approval process for Korean manufacturers? - What are the potential time and cost savings of using the MDSAP pathway for B-GMP? - What does the B-GMP process look like for companies without MDSAP certification? - How long does a direct ANVISA on-site audit in Korea typically take? - Can my existing K-GMP certification help me achieve B-GMP compliance? - What is the validity period for a B-GMP certificate obtained through MDSAP versus a direct audit? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. Our integrated approach allows a single registration process to access multiple markets. Whether you're a startup or a multinational, we help you navigate complex requirements like ANVISA's B-GMP. Visit us at https://pureglobal.com, email [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your market entry.